Table 5.
Univariate analysis of prognosis of MM patients (x ± SD)
| Factors | The survival group (n = 64) | The death group (n = 58) | χ2 value | P |
|---|---|---|---|---|
| Age (y) | 0.728 | .467 | ||
| <60 | 51 (79.69) | 43 (74.14) | ||
| ≥60 | 13 (20.31) | 15 (25.86) | ||
| Gender | 0.587 | .444 | ||
| Male | 45 (70.31) | 37 (63.79) | ||
| Female | 19 (29.69) | 21 (36.21) | ||
| Smoking history | 0.612 | .434 | ||
| Yes | 33 (51.56) | 34 (58.62) | ||
| No | 31 (48.44) | 24 (41.38) | ||
| AFP level | 9.946 | .002 | ||
| ≤400 ng/mL | 32 (50) | 13 (22.41) | ||
| >40 0ng/mL | 32 (50) | 45 (77.59) | ||
| Tumor location | 0.081 | .776 | ||
| Right half liver | 37 (57.81) | 35 (60.34) | ||
| Left half liver | 27 (42.19) | 23 (39.66) | ||
| WBC | 0.229 | .632 | ||
| <4 × 109/L | 27 (42.19) | 22 (37.93) | ||
| ≥4 × 109/L | 37 (57.81) | 36 (62.07) | ||
| PLT | 0.698 | .404 | ||
| <100 × 109/L | 39 (60.94) | 31 (53.45) | ||
| ≥100 × 109/L | 25 (39.06) | 27 (46.55) | ||
| Lesion size | 5.334 | .021 | ||
| ≤3 cm | 42 (65.63) | 26 (44.83) | ||
| >3 cm | 22 (34.38) | 32 (55.17) | ||
| Bilirubin | 0.618 | .432 | ||
| ≤1.5 mg/dL | 21 (32.81) | 23 (39.66) | ||
| >1.5 mg/dL | 43 (67.19) | 35 (60.34) | ||
| collateral portal vein circulation | 6.229 | .013 | ||
| Yes | 33 (51.56) | 17 (29.31) | ||
| No | 31 (48.44) | 41 (70.69) | ||
| Treatment methods | 9.239 | .002 | ||
| TACE | 20 (31.25) | 34 (58.62) | ||
| HIFU combined with TACE | 44 (68.75) | 24 (41.38) |